Saturday 17 October 2026
Export SLXN’s income statement to Excel — free account
Silexion Therapeutics Corp
SLXN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 88.0%, free cash flow fell 16.6% and total debt fell 47.0%, each against the same quarter a year earlier.
0.15
0.04
−21.05%
Follow SLXN
Silexion Therapeutics Corp (SLXN) P/E ratio
Silexion Therapeutics Corp has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.6× (March 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 6.6×
Ten-year median
0.0×
Current reading's percentile
80
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SLXN Silexion Therapeutics Corp | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| GOVX GeoVax Labs Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| ONCO Onconetix, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)